AP231A - Antimalarial composition. - Google Patents

Antimalarial composition. Download PDF

Info

Publication number: AP231A
Authority: AP; ARIPO
Prior art keywords: effective amount; pharmaceutical composition; benflumetol; artemether; compound
Prior art date: 1990-08-08

Application number

APAP/P/1991/000275A

Other languages

English (en)

Other versions

AP9100275A0 (en

Inventor

Yiqing Zhou

Dianxi Ning

Shufen Wang

Deben Ding

Guofu Li

Chengqoi Shan

Guangyu Liu

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-08-08

Filing date

1991-06-12

Publication date

1993-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25742651&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP231(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-06-12 Application filed by Novartis Ag filed Critical Novartis Ag

1991-07-31 Publication of AP9100275A0 publication Critical patent/AP9100275A0/xx

1993-01-31 Application granted granted Critical

1993-01-31 Publication of AP231A publication Critical patent/AP231A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 31
239000003430 antimalarial agent Substances 0.000 title abstract description 16
230000000078 anti-malarial effect Effects 0.000 title description 13
DYLGFOYVTXJFJP-MYYYXRDXSA-N lumefantrine Chemical compound C12=CC(Cl)=CC=C2C=2C(C(O)CN(CCCC)CCCC)=CC(Cl)=CC=2\C1=C/C1=CC=C(Cl)C=C1 DYLGFOYVTXJFJP-MYYYXRDXSA-N 0.000 claims abstract description 37
229960004985 lumefantrine Drugs 0.000 claims abstract description 36
229960000981 artemether Drugs 0.000 claims abstract description 30
SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 claims abstract description 30
201000004792 malaria Diseases 0.000 claims abstract description 29
BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical group C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims abstract description 16
230000002195 synergetic effect Effects 0.000 claims abstract description 13
239000008194 pharmaceutical composition Substances 0.000 claims description 25
150000001875 compounds Chemical class 0.000 claims description 20
238000000034 method Methods 0.000 claims description 16
239000002552 dosage form Substances 0.000 claims description 13
229960004191 artemisinin Drugs 0.000 claims description 11
239000000654 additive Substances 0.000 claims description 8
-1 cyclohexanecarbonyloxy, benzoyloxy Chemical group 0.000 claims description 7
239000001257 hydrogen Substances 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
229960002970 artemotil Drugs 0.000 claims description 6
NLYNIRQVMRLPIQ-XQLAAWPRSA-N artemotil Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OCC)O[C@H]4[C@]32OO[C@@]1(C)O4 NLYNIRQVMRLPIQ-XQLAAWPRSA-N 0.000 claims description 6
229960002521 artenimol Drugs 0.000 claims description 5
FIHJKUPKCHIPAT-AHIGJZGOSA-N artesunate Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@@H](OC(=O)CCC(O)=O)[C@@H]4C FIHJKUPKCHIPAT-AHIGJZGOSA-N 0.000 claims description 5
229960004991 artesunate Drugs 0.000 claims description 5
BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 4
241000282414 Homo sapiens Species 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
239000001301 oxygen Substances 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
241001465754 Metazoa Species 0.000 claims description 2
229940079593 drug Drugs 0.000 abstract description 13
239000003814 drug Substances 0.000 abstract description 13
239000007909 solid dosage form Substances 0.000 abstract 1
239000003826 tablet Substances 0.000 description 22
239000002775 capsule Substances 0.000 description 11
230000000694 effects Effects 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
206010037660 Pyrexia Diseases 0.000 description 6
230000008034 disappearance Effects 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
239000008187 granular material Substances 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
230000001225 therapeutic effect Effects 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
241000224017 Plasmodium berghei Species 0.000 description 4
241000223960 Plasmodium falciparum Species 0.000 description 4
239000013078 crystal Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000008107 starch Substances 0.000 description 4
239000000829 suppository Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 3
WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
229920001353 Dextrin Polymers 0.000 description 3
239000004375 Dextrin Substances 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
206010035503 Plasmodium vivax infection Diseases 0.000 description 3
201000009976 Plasmodium vivax malaria Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
208000005469 Vivax Malaria Diseases 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
229960003677 chloroquine Drugs 0.000 description 3
WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
235000019425 dextrin Nutrition 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
229960001962 mefloquine Drugs 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
244000045947 parasite Species 0.000 description 3
230000000505 pernicious effect Effects 0.000 description 3
229920000136 polysorbate Polymers 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
208000002476 Falciparum Malaria Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241001529936 Murinae Species 0.000 description 2
201000011336 Plasmodium falciparum malaria Diseases 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
229960001444 amodiaquine Drugs 0.000 description 2
229930101531 artemisinin Natural products 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000001035 drying Methods 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
239000002547 new drug Substances 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
229930183339 qinghaosu Natural products 0.000 description 2
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
238000011160 research Methods 0.000 description 2
238000007873 sieving Methods 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
229960004793 sucrose Drugs 0.000 description 2
239000002511 suppository base Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000011885 synergistic combination Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
208000037972 tropical disease Diseases 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
235000001405 Artemisia annua Nutrition 0.000 description 1
240000000011 Artemisia annua Species 0.000 description 1
241001481710 Cerambycidae Species 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
241000223801 Plasmodium knowlesi Species 0.000 description 1
208000035999 Recurrence Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000005336 allyloxy group Chemical group 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
229940061229 artemether 20 mg Drugs 0.000 description 1
230000037396 body weight Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
231100000045 chemical toxicity Toxicity 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000008450 motivation Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000006201 parenteral dosage form Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
229960005179 primaquine Drugs 0.000 description 1
INDBQLZJXZLFIT-UHFFFAOYSA-N primaquine Chemical compound N1=CC=CC2=CC(OC)=CC(NC(C)CCCN)=C21 INDBQLZJXZLFIT-UHFFFAOYSA-N 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
WKSAUQYGYAYLPV-UHFFFAOYSA-N pyrimethamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C=C1 WKSAUQYGYAYLPV-UHFFFAOYSA-N 0.000 description 1
229960000611 pyrimethamine Drugs 0.000 description 1
229960001404 quinidine Drugs 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
238000010998 test method Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

APAP/P/1991/000275A 1990-08-08 1991-06-12 Antimalarial composition. AP231A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN90106722A CN1058717A (zh)	1990-08-08	1990-08-08	抗疟新药—复方蒿甲醚及其制备方法
CN91102575A CN1085527C (zh)	1990-08-08	1991-04-24	增效复方抗疟药本芴醇的制备方法

Publications (2)

Publication Number	Publication Date
AP9100275A0 AP9100275A0 (en)	1991-07-31
AP231A true AP231A (en)	1993-01-31

Family

ID=25742651

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1991/000275A AP231A (en)	1990-08-08	1991-06-12	Antimalarial composition.

Country Status (26)

Country	Link
US (1)	US5677331A (fr)
EP (1)	EP0500823B1 (fr)
JP (1)	JP2562857B2 (fr)
KR (1)	KR100221689B1 (fr)
CN (2)	CN1058717A (fr)
AP (1)	AP231A (fr)
AT (1)	ATE135209T1 (fr)
AU (1)	AU642747B2 (fr)
CA (1)	CA2065285C (fr)
DE (2)	DE69117922T2 (fr)
DK (1)	DK0500823T3 (fr)
EG (1)	EG19905A (fr)
ES (1)	ES2084168T3 (fr)
FI (1)	FI921491A7 (fr)
GR (1)	GR3019313T3 (fr)
HU (1)	HU227345B1 (fr)
IE (1)	IE72095B1 (fr)
IL (1)	IL98463A (fr)
LU (1)	LU90844I2 (fr)
MA (1)	MA22176A1 (fr)
NL (1)	NL300048I2 (fr)
NZ (1)	NZ238477A (fr)
PT (1)	PT97945B (fr)
SA (1)	SA91120263B1 (fr)
WO (1)	WO1992002217A1 (fr)
ZA (1)	ZA914490B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5637594A (en) *	1991-04-11	1997-06-10	Ciba Geigy Corporation	Antimalarial synergistic compositions containing benflumetol
AU668376B2 (en) *	1992-02-07	1996-05-02	Novartis Ag	Antimalarial synergistic compositions containing benflumetol
WO1995027964A1 (fr) *	1994-04-12	1995-10-19	Qualcomm Incorporated	Procede et dispositif de transport de fret au moyen d'un systeme de navigation par satellite
US5657088A (en) *	1995-12-22	1997-08-12	Cirrus Logic, Inc.	System and method for extracting caption teletext information from a video signal
US6136847A (en) *	1996-12-02	2000-10-24	Johns Hopkins University	Water-soluble trioxanes as potent and safe antimalarial agents
CH692321A5 (de)	1997-11-03	2002-05-15	Mepha Ag	Pharmazeutisch wirksame Zusammensetzung, welche eine gegen Malariaparasiten wirksame Substanz enthält.
CO5040050A1 (es)	1998-06-25	2001-05-29	Novartis Ag	Compuestos de 2-amino-1-(9-arilmetilidina-2,7-dicloro-9h- fluoren-4-ilo)-etanoles n-sustituidos, procedimientos para su obtencion y preparados farmaceuticos que los contienen .
IN191696B (fr) *	1999-02-12	2003-12-20	Council Scient Ind Res
EP1267864A1 (fr) *	2000-03-31	2003-01-02	Council Of Scientific & Industrial Research	Formulation synergetique anti-paludique
JPWO2002032905A1 (ja) *	2000-10-20	2004-02-26	味の素株式会社	マラリア治療のための医薬組成物、ドーズおよび方法
US7842719B2 (en) *	2002-10-31	2010-11-30	Kemin Foods, L.C.	Use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis C, bovine viral diarrhea and classical swine fever virus
WO2004075817A2 (fr) *	2003-02-26	2004-09-10	Vrije Universiteit Brussel	Composition pharmaceutique pouvant etre mise en suspension
WO2005023304A2 (fr) *	2003-09-04	2005-03-17	Cipla Limited	Compositions antipaludeennes et procede associe
US20110206636A1 (en) *	2003-09-16	2011-08-25	Kemin Foods, LLC	Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus
WO2007017646A2 (fr) *	2005-08-05	2007-02-15	Cipla Limited	Composition antimalarienne
WO2007036947A1 (fr) *	2005-09-30	2007-04-05	Ipca Laboratories Limited	Composition anti-paludéenne à libération retardée
EP2034986A2 (fr) *	2006-06-26	2009-03-18	Ranbaxy Laboratories Limited	Compositions pharmaceutiques pour l'administration orale à des doses élévées d'arteméther et de luméfantrine
CN100463669C (zh) *	2006-08-31	2009-02-25	广州市医药工业研究所	复方蒿甲醚自乳化剂
WO2008098586A1 (fr)	2007-02-13	2008-08-21	Dafra Pharma N.V.	Composition de support pharmaceutique et composition pharmaceutique
CH700941B1 (de) *	2007-12-04	2010-11-15	Mepha Ag	Pharmazeutische Zusammensetzung zur Behandlung von Malaria.
FR2926993B1 (fr) *	2008-02-06	2011-03-11	Sanofi Aventis	Association entre un sel de bis-thiazolium ou l'un de ses precurseurs et l'artemisinine ou l'un de ses derives pour le traitement du paludisme
WO2010004573A1 (fr) *	2008-07-07	2010-01-14	Ipca Laboratories Limited	Composition pharmaceutique synergiste antipaludique
US10561157B2 (en) *	2012-03-30	2020-02-18	Sudzucker Aktiengesellschaft Mannheim/Ochsenfurt	Rolling compound powders for applying on the surface of chewing gum core materials
CN103251584A (zh) *	2013-05-09	2013-08-21	西安力邦制药有限公司	注射用蒿甲醚/本芴醇复方脂肪乳的制备及其在疟疾治疗中的应用
WO2015140709A1 (fr) *	2014-03-19	2015-09-24	Novartis Ag	Formes posologiques pharmaceutiques solides
CN110691597A (zh) *	2017-04-24	2020-01-14	诺华股份有限公司	2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案
CN113599382B (zh) *	2021-08-20	2023-01-03	兰州大学	喹啉类衍生物在制备治疗糖尿病及其并发症药物中的应用
CN116410197A (zh) *	2023-03-03	2023-07-11	五邑大学	一种喹啉环内过氧桥环衍生物及其制备方法
CN116747218B (zh) *	2023-08-21	2023-10-31	山东省中医药研究院	百秋李醇、百秋李醇复合抗疟组合物及制备抗疟原虫药物中的应用
LU506390B1 (en)	2024-02-09	2025-08-11	L2R Sas	Oil-in-water jellified emulsion for use in anti-malarial treatment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0362810A1 (fr) *	1988-10-07	1990-04-11	Hoechst Aktiengesellschaft	Compositions contre la malaria et méthodes de traitement utilisant la quinidine, artémisinine ou leurs dérivés

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN85100781B (zh) *	1985-04-01	1988-07-06	广西壮族自治区桂林制药厂	抗疟药物青蒿酯的制备方法
CN85100978A (zh) *	1985-04-01	1986-08-13	中医研究院中药研究所	还原青蒿素的生产工艺
CN87101346A (zh) *	1987-06-09	1988-03-09	山东省中医药研究所	青蒿素提取工艺
CN1029680C (zh) *	1988-11-10	1995-09-06	军事医学科学院微生物流行病研究所	抗疟新药苯芴醇的合成新工艺

1990
- 1990-08-08 CN CN90106722A patent/CN1058717A/zh not_active Withdrawn
1991
- 1991-04-24 CN CN91102575A patent/CN1085527C/zh not_active Expired - Lifetime
- 1991-06-05 DE DE69117922T patent/DE69117922T2/de not_active Expired - Lifetime
- 1991-06-05 AU AU79549/91A patent/AU642747B2/en not_active Expired
- 1991-06-05 WO PCT/EP1991/001033 patent/WO1992002217A1/fr not_active Ceased
- 1991-06-05 JP JP3510033A patent/JP2562857B2/ja not_active Expired - Lifetime
- 1991-06-05 EP EP91911449A patent/EP0500823B1/fr not_active Expired - Lifetime
- 1991-06-05 FI FI921491A patent/FI921491A7/fi unknown
- 1991-06-05 KR KR1019920700800A patent/KR100221689B1/ko not_active Expired - Lifetime
- 1991-06-05 HU HU9201528A patent/HU227345B1/hu unknown
- 1991-06-05 DK DK91911449.6T patent/DK0500823T3/da active
- 1991-06-05 DE DE2001199038 patent/DE10199038I2/de active Active
- 1991-06-05 ES ES91911449T patent/ES2084168T3/es not_active Expired - Lifetime
- 1991-06-05 AT AT91911449T patent/ATE135209T1/de not_active IP Right Cessation
- 1991-06-05 CA CA002065285A patent/CA2065285C/fr not_active Expired - Lifetime
- 1991-06-10 MA MA22451A patent/MA22176A1/fr unknown
- 1991-06-11 EG EG35991A patent/EG19905A/xx active
- 1991-06-11 NZ NZ238477A patent/NZ238477A/xx not_active IP Right Cessation
- 1991-06-12 AP APAP/P/1991/000275A patent/AP231A/en active
- 1991-06-12 IE IE198991A patent/IE72095B1/en not_active IP Right Cessation
- 1991-06-12 ZA ZA914490A patent/ZA914490B/xx unknown
- 1991-06-12 IL IL9846391A patent/IL98463A/en not_active IP Right Cessation
- 1991-06-12 PT PT97945A patent/PT97945B/pt not_active IP Right Cessation
- 1991-12-10 SA SA91120263A patent/SA91120263B1/ar unknown
1994
- 1994-03-23 US US08/216,440 patent/US5677331A/en not_active Expired - Lifetime
1996
- 1996-03-14 GR GR960400492T patent/GR3019313T3/el unknown
2001
- 2001-07-19 NL NL300048C patent/NL300048I2/nl unknown
- 2001-07-19 LU LU90844C patent/LU90844I2/fr unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0362810A1 (fr) *	1988-10-07	1990-04-11	Hoechst Aktiengesellschaft	Compositions contre la malaria et méthodes de traitement utilisant la quinidine, artémisinine ou leurs dérivés

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Parasitology 90, 1985, pp. 705-715, espec. 709-710 *

Also Published As

Publication number	Publication date
ES2084168T3 (es)	1996-05-01
IL98463A0 (en)	1992-07-15
CN1085527C (zh)	2002-05-29
JP2562857B2 (ja)	1996-12-11
HU227345B1 (en)	2011-04-28
ZA914490B (en)	1992-03-25
DE10199038I2 (de)	2007-01-04
PT97945A (pt)	1992-04-30
AU642747B2 (en)	1993-10-28
NL300048I1 (nl)	2001-10-01
MA22176A1 (fr)	1991-12-31
PT97945B (pt)	1998-11-30
LU90844I2 (fr)	2002-01-24
EP0500823B1 (fr)	1996-03-13
WO1992002217A1 (fr)	1992-02-20
NZ238477A (en)	1992-12-23
IE911989A1 (en)	1992-02-12
NL300048I2 (nl)	2002-03-01
CA2065285C (fr)	2000-05-09
CN1065993A (zh)	1992-11-11
CA2065285A1 (fr)	1992-02-09
SA91120263B1 (ar)	2004-08-31
DE10199038I1 (de)	2001-11-22
DK0500823T3 (da)	1996-04-01
JPH05501568A (ja)	1993-03-25
IE72095B1 (en)	1997-03-12
HK1000312A1 (en)	1998-02-27
KR920702217A (ko)	1992-09-03
IL98463A (en)	1995-10-31
EP0500823A1 (fr)	1992-09-02
HUT61664A (en)	1993-03-01
KR100221689B1 (ko)	1999-09-15
AP9100275A0 (en)	1991-07-31
FI921491L (fi)	1992-04-03
EG19905A (en)	1996-05-31
CN1058717A (zh)	1992-02-19
DE69117922D1 (de)	1996-04-18
US5677331A (en)	1997-10-14
ATE135209T1 (de)	1996-03-15
DE69117922T2 (de)	1996-09-05
FI921491A0 (fi)	1992-04-03
GR3019313T3 (en)	1996-06-30
HU9201528D0 (en)	1992-08-28
AU7954991A (en)	1992-03-02
FI921491A7 (fi)	1992-04-03

Publication	Publication Date	Title
AP231A (en)	1993-01-31	Antimalarial composition.
JPH02157223A (ja)	1990-06-18	抗マラリア剤組成物
AU614515B2 (en)	1991-09-05	A pharmaceutical combination for the prophylaxis and therapy of malaria
JPH0232093A (ja)	1990-02-01	抗レトロウィルスジフルオロ化ヌクレオシド類
WO2005023304A2 (fr)	2005-03-17	Compositions antipaludeennes et procede associe
DE69936186T2 (de)	2008-01-24	Dihydroartemisinin-Formulierung zur Behandlung von verschiedenen Typen von Malaria
AU668376B2 (en)	1996-05-02	Antimalarial synergistic compositions containing benflumetol
EP0214933A2 (fr)	1987-03-18	Préparations à base de mélanges pour le traitement de la malaria
US5637594A (en)	1997-06-10	Antimalarial synergistic compositions containing benflumetol
HK1000312B (en)	1998-02-27	Antimalarial compositions
JP2001507672A (ja)	2001-06-12	Ｃｉｓ―縮合シクロペンテノ―１，２，４―トリオキサン誘導体を含有する抗マラリア組成物
EP0583439B1 (fr)	1999-03-17	Composition synergiques antipaludiques contenant du benflumetol
DE69323941T2 (de)	1999-08-26	Synergistische malariamittel, die benflumetol enthalten
PL172590B1 (pl)	1997-10-31	Synergiczny srodek przeciwmalaryczny PL
JPH0643306B2 (ja)	1994-06-08	癌細胞転移抑制剤
JPH04230322A (ja)	1992-08-19	抗マラリア医薬組成物
JP2001503371A (ja)	2001-03-13	Ｃｄ８＋細胞の個数を減少させるイプリフラボンの使用
JPH01275531A (ja)	1989-11-06	癌細胞転移抑制剤
JPH07165576A (ja)	1995-06-27	３ーオキシゲルミルプロピオン酸化合物を主成分とするｃ型ウイルス性肝炎の予防及び治療剤